How Does Moderna Stock Compare With Peers?
With Moderna surging 6.7% in a Day, it makes sense to re-evaluate vs its peers. Consistently assessing alternatives is core to a sound investment approach. Here is how Moderna (MRNA) stock stacks up against its peers in size, valuation, growth and margin.
- MRNA’s operating margin of -157.3% is negative, lowest among peers; CVAC has 41.1%.
- MRNA’s revenue growth of -56.4% in the last 12 months is negative, lagging PFE, ALNY, SRPT, CVAC.
- MRNA’s stock is down 38.2% in last 1 year, underperforming PFE, ALNY, CVAC, and currently trades at a PE of -3.3.
As a quick background, Moderna develops mRNA-based therapeutics and vaccines for infectious diseases, immuno-oncology, rare, cardiovascular, and auto-immune diseases, with 44 programs including 26 clinical trials across seven modalities.
A single stock can be risky, but there is a huge value to a broader, diversified approach. Strategic asset allocation and diversification help you stay invested. Did you know investors who panicked out of the S&P in 2020 lost significant upside that followed? Trefis High Quality Portfolio and Empirical Asset Management’s asset allocation approach are designed to reduce volatility so you can stay the course.
| MRNA | PFE | ALNY | SRPT | CVAC | |
|---|---|---|---|---|---|
| Market Cap ($ Bil) | 10.3 | 145.0 | 59.4 | 1.8 | 1.2 |
| Revenue ($ Bil) | 2.2 | 62.8 | 3.2 | 2.4 | 0.5 |
| PE Ratio | -3.3 | 14.8 | 1,363.7 | -6.6 | 6.1 |
| LTM Revenue Growth | -56.4% | 3.9% | 53.2% | 47.1% | 675.2% |
| LTM Operating Margin | -157.3% | 24.6% | 8.2% | -3.6% | 41.1% |
| LTM FCF Margin | -120.9% | 16.5% | 6.9% | -16.1% | 38.4% |
| 12M Market Return | -38.2% | 4.3% | 61.5% | -84.7% | 89.2% |
Why does this matter? MRNA just went up 11.2% in a week – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell MRNA Stock to see if Moderna holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through MRNA Dip Buyer Analysis lens.
- How To Earn 9.2% Yield While Waiting to Buy LLY 30% Cheaper
- Could Accenture Stock’s Cash Flow Spark the Next Rally?
- Years of Rewards: $35 Bil From Charter Communications Stock
- McDonald’s Stock Capital Return Hits $35 Bil
- Palo Alto Networks Stock at Support Zone – Bargain or Trap?
- Super Micro Computer Stock Pulls Back to Support – Smart Entry?
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -56.4% | -52.6% | -64.2% | 6.4% |
| PFE | 3.9% | 6.8% | -41.1% | 24.5% |
| ALNY | 53.2% | 23.0% | 76.2% | 22.9% |
| SRPT | 47.1% | 53.0% | 33.3% | 32.9% |
| CVAC | 675.2% | 895.5% | -20.3% | -34.5% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -157.3% | -123.3% | -62.8% | 49.9% |
| PFE | 24.6% | 23.3% | 7.1% | 36.7% |
| ALNY | 8.2% | -7.9% | -15.4% | -75.7% |
| SRPT | -3.6% | 11.5% | -21.5% | -57.5% |
| CVAC | 41.1% | 33.2% | -510.1% | -370.0% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -3.3 | -4.5 | -8.1 | 8.5 |
| PFE | 14.8 | 18.7 | 76.7 | 9.2 |
| ALNY | 1363.7 | -108.0 | -54.3 | -25.6 |
| SRPT | -6.6 | 55.8 | -16.6 | -16.1 |
| CVAC | 6.1 | 4.7 | -3.6 | -4.6 |
While peer comparison is critical, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.